Kaitai Capital

Kaitai Capital is a professional investment management organization based in Hangzhou, China. Founded in 2009, the firm specializes in innovative investments, industrial investments, and wealth management services. Its investment focus spans various sectors, including biopharma, healthcare services, agriculture technology, consumer business, and digital technology. The firm is recognized as a global leader by HFM, Preqin, BarclayHedge, and China Hedge Fund Ranking.

The firm's investment strategy encompasses multiple stages, from seed to late-stage investments, and it primarily focuses on the Chinese market. Kaitai Capital has a diverse portfolio, with investments in companies such as OncoC4, Rgenta Therapeutics, Teon Therapeutics, Forkhead BioTherapeutics, and JeniVision. The firm is committed to creating long-term, sustainable wealth for its clients through a proactive approach to investments in emerging markets.

Kaitai Capital's philosophy centers on empowering entrepreneurs and management teams to navigate the challenges and opportunities of globalization and sustainable digital transformation. The firm values community, innovation, and resilience, reflecting these principles in its work and interactions with portfolio companies. By fostering a collaborative environment, Kaitai Capital aims to build stronger returns on investment and contribute to the growth and success of its investee companies.